About GT Medical Technologies
GT Medical Technologies is a company based in Tempe (United States) founded in 2017 by Theresa Thomas, Emad Youssef, David G Brachman, Heyoung McBride, and Peter Nakaji. GT Medical Technologies has raised $129.94 million across 7 funding rounds from investors including Horizon Tech Finance, MVM Partners and Gilde Healthcare. GT Medical Technologies offers products and services including GammaTile Therapy. GT Medical Technologies operates in a competitive market with competitors including HEPTA Medical, Curative Biotech, Laevoroc Oncology, Rongsheng Medical and InCephalo, among others.
- Headquarter Tempe, United States
- Founders Theresa Thomas, Emad Youssef, David G Brachman, Heyoung McBride, Peter Nakaji
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$129.94 M (USD)
in 7 rounds
-
Latest Funding Round
$53.3 M (USD), Series C
Dec 23, 2024
-
Investors
Horizon Tech Finance
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GT Medical Technologies
GT Medical Technologies offers a comprehensive portfolio of products and services, including GammaTile Therapy.
Surgically targeted radiation to treat brain tumors and minimize side effects
People of GT Medical Technologies
Unlock access to complete
Funding Insights of GT Medical Technologies
GT Medical Technologies has successfully raised a total of $129.94M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $53.3 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series C — $53.3M
-
First Round
First Round
(06 Dec 2017)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series C - GT Medical Technologies | Valuation | Evidity Health Capital | |
| Sep, 2024 | Amount | Debt – Venture - GT Medical Technologies | Valuation |
investors |
|
| Mar, 2023 | Amount | Series C - GT Medical Technologies | Valuation | Gilde Healthcare |
Investors in GT Medical Technologies
GT Medical Technologies has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Horizon Tech Finance, MVM Partners and Gilde Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Structured debt is provided to life sciences and technology firms.
|
Founded Year | Domain | Location | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Founded Year | Domain | Location | |
|
Private equity investments in healthcare companies are managed.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GT Medical Technologies
Financial Statements - GT Medical Technologies
Gt Medical Technologies Comparisons
Competitors of GT Medical Technologies
GT Medical Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HEPTA Medical, Curative Biotech, Laevoroc Oncology, Rongsheng Medical and InCephalo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Minimally invasive ablation catheters for pulmonary nodules are developed endoscopically.
|
|
| domain | founded_year | HQ Location |
Therapeutic drugs for cancer, eye, and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pancreatic, ovarian, breast, and brain cancers are developed.
|
|
| domain | founded_year | HQ Location |
Developer of precision internal radiation interventional therapy for tumors
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurological disorders are developed using barrier-retaining technology.
|
Frequently Asked Questions about GT Medical Technologies
GT Medical Technologies was founded in 2017.
GT Medical Technologies is headquartered in Tempe, United States. It is registered at Tempe, Arizona, United States.
GT Medical Technologies is a funded company, having raised a total of $129.94M across 7 funding rounds to date. The company's 1st funding round was a Series C of $45M, raised on Dec 06, 2017.
GT Medical Technologies providers medical devices for radiation therapy for brain tumor treatment. It offers GammaTile Therapy is surgically targeted radiation therapy (STaRT) for patients with recurrent brain tumors. The technology uses a combination of a collagen matrix with brachytherapy (radiation) seeds. The technology of the compnay is protected by 10 US and 2 Canadian issued patents, and 1 EPO patent.
GT Medical Technologies's top competitors include Laevoroc Oncology, HEPTA Medical and Curative Biotech.
GT Medical Technologies offers GammaTile Therapy.
GT Medical Technologies has 7 investors. Key investors include Horizon Tech Finance, MVM Partners, Gilde Healthcare, MedTech Venture Partners, and BlueStone Venture Partners.